Childhood Immune Thrombocytopenia (ITP) – A Parent-Friendly Guide

9 February2026

(Immune Thrombocytopenia (ITP) is one of the most common bleeding disorders in children. It occurs when the immune system mistakenly destroys platelets, the blood cells responsible for clotting. Low platelet counts can lead to bruising and bleeding, but importantly, most children recover completely. Current guidelines emphasize treating the child’s bleeding symptoms, not just the platelet number.

Why platelets are important

Platelets stop bleeding by forming clots. When platelets are low, bleeding can occur more easily, even after minor injuries.

Common age of presentation

  • Infants and toddlers (1–4 years) – most common
  • School-age children (5–10 years)
  • Adolescents

Common causes and triggers

  • Recent viral infection
  • Immune response after vaccination (rare)
  • Autoimmune tendency
  • In most cases, no identifiable cause

Types of ITP based on duration

  • Newly diagnosed (new onset) ITP: Less than 3 months
  • Persistent ITP: 3–12 months
  • Chronic ITP: More than 12 months

Signs and symptoms

  • Easy bruising
  • Small red or purple skin spots (petechiae)
  • Nosebleeds, gum bleeding
  • Blood blisters in mouth
  • Heavy menstrual bleeding in adolescents

How it is diagnosed

  • Complete blood count: isolated low platelet count
  • Peripheral smear: normal red and white cells
  • Additional tests only if atypical features present

Treatment approach

Observation only:

  • No or mild bleeding

First-line treatments:

  • Short course corticosteroids
  • Intravenous immunoglobulin (IVIG)
  • Anti-D immunoglobulin

Second-line / chronic ITP options:

  • Thrombopoietin receptor agonists
  • Rituximab
  • Rarely splenectomy

Expected response to medications

  • Steroids – platelet rise in 3–7 days
  • IVIG – rise in 24–48 hours
  • Anti-D – rise in 1–3 days
  • TPO receptor agonists – 1–2 weeks
  • Rituximab – weeks

Prognosis

  • 70–80% recover within 6 months
  • Small proportion develop chronic ITP
  • Serious bleeding is rare

Take-home message

Childhood ITP is usually a temporary and manageable condition. Many children need only monitoring. With proper follow-up, most children lead normal, healthy lives.

- Medically reviewed by Dr. Amit Jain (Consultant, Pediatric Hematology-Oncology & Bone Marrow Transplant)

Facebook
Twitter
LinkedIn
Email
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male